Skin Cancer

Cutaneous squamous cell carcinoma should be diagnosed early and treated promptly to avoid complications.

Relatlimab plus nivolumab (Opdualag) shows improved progression-free survival compared with nivolumab monotherapy in patients with unresectable or metastatic melanoma.

Kimmtrak found to be the first therapy to demonstrate a survival benefit for HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma.

Early-stage melanomas at risk of spreading secrete the TGFβ2 growth factor, which causes the downregulation of the AMBRA1 and Loricrin proteins.

The FDA granted priority review to the combination of relatlimab and nivolumab in September 2021 based on the results of this study.

Study results establish LAG-3 inhibition as therapeutically relevant third immune checkpoint pathway

Melanoma is responsible for 80% of skin cancer deaths.

Commonly used medications may influence responses to checkpoint inhibitors among patients with cancer.

FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements.

Pembrolizumab is the first anti-PD-1/anti-PD-L1 therapy to demonstrate a recurrence-free survival benefit in the adjuvant setting for melanoma.

Approximately 40% of patients with stage IV melanoma have brain metastases at diagnosis.

Pembrolizumab (Keytruda) can be used for multiple cancer types, including melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.

The investigators said that these cells, referred to as lymph node resident memory T cells, have been demonstrated to counteract the spread of melanoma in mice.

Cemiplimab is a recombinant human immunoglobulin G4 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

Relatlimab is the first LAG-3-blocking antibody to demonstrate a clinical benefit for patients with melanoma in phase 3 data.

Phase 3 trial results show that the drug reduced the risk of death or reoccurrence by 35% for individuals with high-risk disease compared with the placebo.

Survey participants saw potential for immunotherapy use in earlier stages of several diseases, including melanoma, lung cancer, and bladder or urothelial cancer.

BCC is the most common form of skin cancer and is typically treated with surgical excision. However, excision can be a costly and burdensome treatment, especially for patients with multiple BCC lesions, according to the study.

The FDA has previously granted Orphan Drug designation to nemvaleukin for the treatment of mucosal melanoma.

AQP-modulating agent discovery has proved challenging, but many powerful AQP3 permeating molecules have been identified.

The FDA has granted Orphan Drug Designation (ODD) to alrizomadlin (APG-115, Ascentage Pharma) for the treatment of stage IIB-IV melanoma.

Many individuals underestimate the importance of protecting their skin from the sun.

Patients may consult with their pharmacist regarding appropriate protection methods and treatment options available for common summer skin ailments.

A recent study proved community pharmacies are model settings for skin cancer prevention education in rural communities with insufficient access to health care services.

The approval is based on results from the phase 2 KEYNOTE-629 trial, which found an objective response rate of 50% in adults with recurrent, metastatic, or locally advanced cutaneous squamous cell carcinoma.

Pharmacists’ vast health care knowledge and community accessibility makes them ideal patient liaisons.

The current study analyzed human tumor samples from 6 cancer types: liver, melanoma, colorectal, non-small lung, head and neck, and breast cancer.

Melanoma forms when pigment-producing cells called melanocytes mutate and multiply uncontrollably.

In England, incidence rates of the skin cancer cutaneous malignant melanoma were found to have increased by more than 550% among males and 250% among females since the early 1980s.

The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma.